LIFE Insider Trading
aTYR PHARMA INC | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at aTYR PHARMA INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2017-04-21 02:04 | 2017-04-18 | MENDLEIN JOHN | Director, Officer - CEO and Director | BUY | $3.00 | 2,552 | $7,656 | 327,523 | +0.8% |
| 2016-12-22 19:53 | 2016-12-20 | SCHIMMEL PAUL | Director | BUY | $2.28 | 25,000 | $56,928 | 721,814 | +3.6% |
| 2016-12-22 02:37 | 2016-12-20 | Amanullah Ashraf | Officer - Vice President, Manufacturing | BUY | $2.25 | 11,000 | $24,749 | 11,000 | +100.0% |
| 2016-12-21 19:54 | 2016-12-19 | MENDLEIN JOHN | Director, Officer - CEO and Director | BUY | $2.20 | 69,000 | $151,662 | 324,971 | +27.0% |
| 2016-12-20 03:41 | 2016-12-15 | SCHIMMEL PAUL | Director | BUY | $2.48 | 50,000 | $123,885 | 696,814 | +7.7% |
| 2016-05-12 03:54 | 2016-05-09 | Matsuoka Grove | Officer - See Remarks | BUY | $3.04 | 12,412 | $37,729 | 12,412 | +100.0% |
| 2016-04-16 00:46 | 2016-04-14 | SCHIMMEL PAUL | Director | BUY | $4.18 | 66,219 | $276,934 | 53,012 | +100.0% |
| 2016-04-15 02:20 | 2016-04-13 | SCHIMMEL PAUL | Director | BUY | $3.85 | 9,835 | $37,865 | 249,962 | +4.1% |
| 2016-04-14 01:34 | 2016-04-12 | SCHIMMEL PAUL | Director | BUY | $3.71 | 9,127 | $33,901 | 240,127 | +4.0% |
| 2016-04-14 01:32 | 2016-04-11 | SCHIMMEL PAUL | Director | BUY | $3.57 | 32,659 | $116,534 | 233,581 | +16.3% |
| 2016-04-12 22:57 | 2016-04-11 | SCHIMMEL PAUL | Director | BUY | $3.57 | 32,659 | $116,534 | 220,231 | +17.4% |
| 2016-04-11 19:39 | 2016-04-08 | SCHIMMEL PAUL | Director | BUY | $3.22 | 85,000 | $273,649 | 187,572 | +82.9% |
| 2016-04-08 19:19 | 2016-04-07 | SCHIMMEL PAUL | Director | BUY | $3.19 | 40,000 | $127,584 | 102,572 | +63.9% |
| 2016-04-07 22:25 | 2016-04-05 | MENDLEIN JOHN | Director, Officer - CEO and Director | BUY | $3.52 | 2,500 | $8,800 | 250,971 | +1.0% |
| 2016-04-07 22:40 | 2016-04-06 | SCHIMMEL PAUL | Director | BUY | $3.20 | 25,000 | $80,000 | 62,572 | +66.5% |
| 2016-04-07 02:19 | 2016-04-05 | MENDLEIN JOHN | Director, Officer - CEO and Director | BUY | $3.55 | 2,500 | $8,875 | 248,471 | +1.0% |
| 2016-04-07 02:19 | 2016-04-05 | SCHIMMEL PAUL | Director | BUY | $3.52 | 25,000 | $88,118 | 37,572 | +198.9% |
| 2015-05-15 04:24 | 2015-05-12 | AKKARAJU SRINIVAS | Director, Other | BUY | $14.00 | 320,000 | $4,480,000 | 1,866,126 | +20.7% |
| 2015-05-15 04:19 | 2015-05-12 | Sofinnova Venture Partners IX, L.P. | 10% owner | BUY | $14.00 | 320,000 | $4,480,000 | 1,866,126 | +20.7% |
| 2015-05-13 20:00 | 2015-05-12 | Flynn James E | 10% owner, Other | BUY | $14.00 | 50,000 | $700,000 | 255,764 | +24.3% |
| 2013-05-30 19:51 | 2013-05-29 | UPRICHARD DAVID C | Director | SELL | $74.04 | 2,010 | $148,820 | 2,930 | -40.7% |
| 2013-05-30 01:58 | 2013-05-24 | COTTINGHAM JOHN A | Officer - Chief Legal Officer | OPT+S | $74.03 | 60,000 | $4,442,016 | 8,231 | 0.0% |
| 2012-12-12 23:05 | 2012-12-11 | LORIMIER BRADLEY G | Director | OPT+S | $51.06 | 20,000 | $1,021,180 | 8,200 | 0.0% |
| 2012-11-21 21:40 | 2012-11-19 | GRIMM DONALD W | Director | SELL | $47.94 | 12,052 | $577,733 | 0 | -100.0% |
| 2012-11-07 22:21 | 2012-11-06 | RICHARD KELLI | Officer - Chief Accounting Officer | SELL | $49.19 | 6,194 | $304,708 | 5,422 | -53.3% |
| 2012-10-17 00:26 | 2012-10-15 | LEVINE ARNOLD J | Director | OPT+S | $48.52 | 6,958 | $337,602 | 1,081 | 0.0% |
| 2012-09-19 02:30 | 2012-09-18 | LUCIER GREGORY T | Officer - Chief Executive Officer | SELL | $50.00 | 169,868 | $8,493,400 | 207,188 | -45.1% |
| 2012-05-04 01:01 | 2012-05-01 | LORIMIER BRADLEY G | Director | OPT+S | $46.55 | 20,000 | $930,908 | 8,200 | 0.0% |
| 2012-05-02 03:22 | 2012-04-27 | ANDREWS RONALD ASBURY | Officer - President, Medical Sciences | BUY | $46.49 | 3,330 | $154,814 | 3,330 | +100.0% |
| 2012-03-16 20:23 | 2012-03-15 | UPRICHARD DAVID C | Director | SELL | $46.08 | 200 | $9,216 | 52 | -79.4% |
| 2012-03-12 19:48 | 2012-03-09 | UPRICHARD DAVID C | Director | SELL | $46.60 | 100 | $4,660 | 252 | -28.4% |
| 2012-03-09 22:11 | 2012-03-08 | UPRICHARD DAVID C | Director | SELL | $46.57 | 200 | $9,313 | 352 | -36.2% |
| 2012-02-29 03:56 | 2012-02-27 | UPRICHARD DAVID C | Director | SELL | $47.66 | 500 | $23,829 | 552 | -47.5% |
| 2012-01-26 22:33 | 2012-01-25 | DITTAMORE RAYMOND V | Director | OPT+S | $50.65 | 20,000 | $1,013,000 | 4,052 | 0.0% |
| 2011-11-23 22:23 | 2011-11-22 | Leddy Peter Michael | Officer - SVP, Global Human Resources | SELL | $36.74 | 2,474 | $90,895 | 27,525 | -8.2% |
| 2011-08-25 01:07 | 2011-08-22 | Pescovitz Ora H. | Director | BUY | $36.16 | 550 | $19,888 | 1,133 | +94.3% |
| 2011-08-24 20:23 | 2011-08-22 | Stevenson Mark | Officer - President & COO | BUY | $36.20 | 5,000 | $181,000 | 49,699 | +11.2% |
| 2011-08-06 00:39 | 2011-08-05 | LUCIER GREGORY T | Officer - Chief Executive Officer | BUY | $42.00 | 10,000 | $420,000 | 335,878 | +3.1% |
| 2011-08-03 23:42 | 2011-08-01 | MATRICARIA RONALD A | Director | BUY | $43.73 | 10,000 | $437,348 | 70,000 | +16.7% |
| 2011-06-08 23:21 | 2011-06-07 | UPRICHARD DAVID C | Director | OPT+S | $51.04 | 1,000 | $51,040 | 52 | 0.0% |
| 2011-05-05 19:38 | 2011-05-03 | UPRICHARD DAVID C | Director | SELL | $55.44 | 4,000 | $221,752 | 52 | -98.7% |
| 2011-05-03 00:41 | 2011-05-02 | Pescovitz Ora H. | Director | BUY | $55.24 | 200 | $11,048 | 200 | +100.0% |
| 2011-03-17 00:47 | 2011-03-15 | LEVINE ARNOLD J | Director | OPT+S | $50.25 | 6,958 | $349,619 | 1,081 | 0.0% |
| 2011-03-16 22:52 | 2011-03-15 | Grossman Paul David | Officer - SVP, Corporate Strategy & Dev. | OPT+S | $50.40 | 18,556 | $935,222 | 4,270 | 0.0% |
| 2011-03-14 20:59 | 2011-03-11 | ADAM GEORGE F JR | Director | OPT+S | $51.12 | 7,828 | $400,188 | 2,747 | 0.0% |
| 2011-02-25 01:43 | 2011-02-24 | UPRICHARD DAVID C | Director | SELL | $52.61 | 100 | $5,261 | 0 | -100.0% |
| 2011-02-19 00:54 | 2011-02-18 | UPRICHARD DAVID C | Director | SELL | $54.17 | 100 | $5,417 | 100 | -50.0% |
| 2011-02-16 21:59 | 2011-02-15 | UPRICHARD DAVID C | Director | SELL | $54.32 | 100 | $5,432 | 200 | -33.3% |
| 2011-02-14 20:51 | 2011-02-11 | UPRICHARD DAVID C | Director | SELL | $53.98 | 100 | $5,398 | 300 | -25.0% |
| 2011-02-11 02:25 | 2011-02-09 | UPRICHARD DAVID C | Director | SELL | $53.55 | 100 | $5,355 | 400 | -20.0% |
How to Interpret $LIFE Trades
Not every insider transaction in aTYR PHARMA INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $LIFE shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for LIFE
Insider activity data for aTYR PHARMA INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $LIFE, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.